Recruiting NA INTERVENTIONAL 2-arm NCT06026267

Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis

Sponsor: Institute of Liver and Biliary Sciences, India

Conditions Liver Cirrhosis Spontaneous Bacterial Peritonitis

Interventions 20% High Dose Albumin 20% Reduced Dose Albumin Standard Medical Treatment

Updated 3 times since 2023 Last updated: Aug 6, 2024 Started: Oct 10, 2023 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06026267, this NA trial focuses on Liver Cirrhosis and Spontaneous Bacterial Peritonitis and remains actively recruiting participants. Sponsored by Institute of Liver and Biliary Sciences, India, it has been updated 3 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting NA
Oct 2023 — Jul 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Liver and Biliary Sciences, India

Data source: Institute of Liver and Biliary Sciences, India

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Delhi, India